In the context of SCLC immunotherapy, the two most extensively studied immune checkpoint receptors are cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, also called CD152) and programmed cell death protein 1 (PD-1, also called CD279) (37). This evidence concerns the gene PDCD1 and small cell lung carcinoma.